

Leamon Christopher P
Form 4
December 19, 2018

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

Check this box
if no longer
subject to
Section 16.
Form 4 or
Form 5
obligations
may continue.
See Instruction
1(b).

**STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF
SECURITIES**

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934,
Section 17(a) of the Public Utility Holding Company Act of 1935 or Section
30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB
Number: 3235-0287
Expires: January 31,
2005
Estimated average
burden hours per
response... 0.5

(Print or Type Responses)

1. Name and Address of Reporting Person *
Leamon Christopher P

(Last) (First) (Middle)

3000 KENT AVE, SUITE A1-100

(Street)

WEST LAFAYETTE, IN 47906

(City) (State) (Zip)

2. Issuer Name **and** Ticker or Trading
Symbol

ENDOCYTE INC [ECYT]

3. Date of Earliest Transaction
(Month/Day/Year)

12/17/2018

4. If Amendment, Date Original
Filed(Month/Day/Year)

5. Relationship of Reporting Person(s) to
Issuer

(Check all applicable)

____ Director ____ 10% Owner
____X____ Officer (give title ____ Other (specify
below) below)

Vice President of Research

6. Individual or Joint/Group Filing(Check
Applicable Line)
____X____ Form filed by One Reporting Person
____ Form filed by More than One Reporting
Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned

1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)	4. Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)	5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Ownership (Instr. 4)
Common Stock	12/17/2018		M	20,000 A	\$ 2.54 142,482 ⁽¹⁾	D	
Common Stock	12/17/2018		M	26,177 A	\$ 3.82 168,659	D	
Common Stock	12/17/2018		M	13,089 A	\$ 7.49 181,748	D	
Common Stock	12/17/2018		M	22,500 A	\$ 9.05 204,248	D	
Common Stock	12/17/2018		M	20,004 A	\$ 3.55 224,252	D	

Edgar Filing: Leamon Christopher P - Form 4

Common Stock	12/17/2018	M	2	A	\$ 5.1	224,254	D
Common Stock	12/17/2018	M	2	A	\$ 3.18	224,256	D

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.

SEC 1474
(9-02)

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)

1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)	5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4, and 5)	6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Underlying Securities (Instr. 3 and 4)		8. Amount or Number of Shares
				Code	V (A) (D)	Date Exercisable	Expiration Date	Title		Amount or Number of Shares
Stock Option (right to buy)	\$ 2.54	12/17/2018		M	20,000	<u>(2)</u>	03/05/2019	Common Stock		20,000
Stock Option (right to buy)	\$ 3.82	12/17/2018		M	26,177	<u>(2)</u>	02/11/2020	Common Stock		26,177
Stock option (right to buy)	\$ 7.49	12/17/2018		M	13,089	<u>(2)</u>	03/11/2021	Common Stock		13,089
Stock Option (right to buy)	\$ 9.05	12/17/2018		M	22,500	<u>(2)</u>	04/14/2021	Common Stock		22,500
Stock option (right to buy)	\$ 3.55	12/17/2018		M	20,004	<u>(2)</u>	02/28/2022	Common Stock		20,004
Stock option	\$ 5.1	12/17/2018		M	2	<u>(2)</u>	02/04/2025	Common Stock		2

(right to
buy)Stock
option
(right to
buy)

\$ 3.18

12/17/2018

M

2

(3)

02/04/2026

Common
Stock

2

Reporting Owners

Reporting Owner Name / Address**Relationships**

Director

10% Owner

Officer

Other

Leamon Christopher P
3000 KENT AVE, SUITE A1-100
WEST LAFAYETTE, IN 47906

Vice President of Research

Signatures

/s/ Michael A. Sherman, Attorney-in-Fact for Christopher P. Leamon (power of attorney
previously filed)

12/19/2018

__Signature of Reporting Person

Date

Explanation of Responses:

* If the form is filed by more than one reporting person, *see* Instruction 4(b)(v).** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. *See* 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

(1) Includes 263 shares acquired under the Endocyte, Inc. 2010 Employee Stock Purchase Plan on December 14, 2018.

(2) The option is fully vested and immediately exercisable.

(3) Shares subject to this option vest 1/4 annually over a period of four years beginning February 4, 2017.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, *see* Instruction 6 for procedure.

Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.